Exact Sciences Announces Third Quarter 2020 Results

Go back to Exact Sciences Announces Third Quarter 2020 Results

UBS Downgrades Exact Sciences (EXAS) to Neutral

October 29, 2020 6:11 AM EDT

UBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).

The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More

Exact Sciences (EXAS) Q3 Revenues Beat

October 27, 2020 7:10 AM EDT

Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($1.46), which may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $408.4 million versus the consensus estimate of $337.37 million. COVID-19 testing revenue was $102.2 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

... More